p53-induced inhibition of Hif-1 causes cardiac dysfunction during pressure overload

Nature

Volumn 446, Issue 7134, 2007, Pages 444-448

  Sano, Masanori ^a   Minamino, Tohru ^a   Toko, Haruhiro ^a   Miyauchi, Hideyuki ^a   Orimo, Masayuki ^a   Qin, Yingjie ^a   Akazawa, Hiroshi ^a   Tateno, Kaoru ^a   Kayama, Yosuke ^a   Harada, Mutsuo ^a   Shimizu, Ippei ^a   Asahara, Takayuki ^b   Hamada, Hirofumi ^c   Tomita, Shuhei ^d   Molkentin, Jeffrey D ^e   Zou, Yunzeng ^f   Komuro, Issei ^a  

^a CHIBA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b INSTITUTE OF BIOMEDICAL RESEARCH AND INNOVATION   (Japan)

^c SAPPORO MEDICAL UNIVERSITY   (Japan)

^d UNIVERSITY OF TOKUSHIMA   (Japan)

^e CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^f FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; HYPOXIA INDUCIBLE FACTOR 1; PROTEIN P53;

CARDIOVASCULAR DISEASE; ENZYME ACTIVITY; INHIBITION; PROTEIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HEART DISEASE; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE PRESSURE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SYSTOLE; SYSTOLIC DYSFUNCTION;

ANIMALS; AORTA; BLOOD PRESSURE; CARDIAC OUTPUT, LOW; CARDIOMEGALY; CORONARY CIRCULATION; DISEASE PROGRESSION; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MICE; NEOVASCULARIZATION, PATHOLOGIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 33947520124     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature05602     Document Type: Article

References (24)

1. Frey, N. & Olson, E. N. Cardiac hypertrophy: the good, the bad, and the ugly. Annu. Rev. Physiol. 65, 45-79 (2003).
2. Levy, D. et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N. Engl. J. Med. 322, 1561-1566 (1990).
3. Marcus, M. L. et al. Abnormalities in the coronary circulation that occur as a consequence of cardiac hypertrophy. Am. J. Med. 75, 62-66 (1983).
4. Tomanek, R. J. Response of the coronary vasculature to myocardial hypertrophy. J. Am. Coll. Cardiol. 15, 528-533 (1990).
5. Giordano, F. J. et al. A cardiac myocyte vascular endothelial growth factor paracrine pathway is required to maintain cardiac function. Proc. Natl Acad. Sci. USA 98, 5780-5785 (2001).
6. Shyu, K. G. et al. Carvedilol prevents cardiac hypertrophy and overexpression of hypoxia-inducible factor-1α and vascular endothelial growth factor in pressureoverloaded rat heart. J. Biomed. Sci. 12, 409-420 (2005).
7. Yoon, Y. S. et al. Progressive attenuation of myocardial vascular endothelial growth factor expression is a seminal event in diabetic cardiomyopathy: restoration of microvascular homeostasis and recovery of cardiac function in diabetic cardiomyopathy after replenishment of local vascular endothelial growth factor. Circulation 111, 2073-2085 (2005).
8. Ingber, D. et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 348, 555-557 (1990).
9. Goldman, C. K. et al. Paracrine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate. Proc. Natl Acad. Sci. USA 95, 8795-8800 (1998).
10. -/-) mice. Proc. Natl Acad. Sci. USA 103, 7165-7169 (2006).
11. Semenza, G. L. Targeting HIF-1 for cancer therapy. Nature Rev. Cancer 3, 721-732 (2003).
12. Pugh, C. W. & Ratcliffe, P. J. Regulation of angiogenesis by hypoxia: role of the HIF system. Nature Med. 9, 677-684 (2003).
13. Blagosklonny, M. V. et al. p53 inhibits hypoxia-inducible factor-stimulated transcription. J. Biol. Chem. 273, 11995-11998 (1998).
14. Ravi, R. et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1α. Genes Dev. 14, 34-44 (2000).
15. Gurova, K. V. et al. Small molecules that reactivate p53 in renal cell carcinoma reveal a NF-κB-dependent mechanism of p53 suppression in tumors. Proc. Natl Acad. Sci. USA 102, 17448-17453 (2005).
16. Fei, P. et al. Bnip3L is induced by p53 under hypoxia, and its knockdown promotes tumor growth. Cancer Cell 6, 597-609 (2004).
17. Kubasiak, L. A., Hernandez, O. M., Bishopric, N. H. & Webster, K. A. Hypoxia and acidosis activate cardiac myocyte death through the Bcl-2 family protein BNIP3. Proc. Natl Acad. Sci. USA 99, 12825-12830 (2002).
18. Kelly, B. D. et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 93, 1074-1081 (2003).
19. Patel, T. H. et al. Constitutively active HIF-1α improves perfusion and arterial remodeling in an endovascular model of limb ischemia. Cardiovasc. Res. 68, 144-154 (2005).
20. Shizukuda, Y. et al. Targeted disruption of p53 attenuates doxorubicin-induced cardiac toxicity in mice. Mol. Cell. Biochem. 273, 25-32 (2005).
21. Takimoto, E. et al. Sodium calcium exchanger plays a key role in alteration of cardiac function in response to pressure overload. FASEB J. 16, 373-378 (2002).
22. Harada, M. et al. G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nature Med. 11, 305-311 (2005).
23. Sohal, D. S. et al. Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ. Res. 89, 20-25 (2001).
24. Tomita, S. et al. Defective brain development in mice lacking the Hif-1α gene in neural cells. Mol. Cell. Biol. 23, 6739-6749 (2003).